CERS - Earnings announcements

Cerus Corporation (NASDAQ:CERS) announced today that its first quarter 2026 financial results will be released on Thursday, April 30, 2026, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event. A repl

2025 Total Revenue of $233.8 million, up 16% from 2024; 2025 Product Revenue of $206.1 million, up 14% from 2024 Strengthened Financial Foundation Through Strong Commercial Execution and Disciplined Operational Management Cerus Corporation (NASDAQ:CERS) announced today financial results for its full year and fourth quarter ended December 31, 2025. "Our strong 2025 results reflect our disciplined execution, as we continued to deliver on our mission of safeguarding the world's blood supply. This past year, we achieved our highest annual kit shipments, enabling an estimated 600,000 patients worldwide to receive INTERCEPT-treated blood components," said William "Obi" Greenman, Cerus' pres

Cerus Corporation (NASDAQ:CERS) announced today its fourth quarter and full-year 2025 financial results will be released on Monday, March 2, 2026, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event. A replay will

Third Quarter Total Revenue up 19% to $60.2 Million; Record Product Revenue of $52.7 Million, Up 15% Year-Over-Year Raising Full-Year 2025 Product Revenue Guidance Range to $202 Million - $204 Million Cerus Corporation (NASDAQ:CERS) announced today financial results for the third quarter ended September 30, 2025, and provided a business update. "We continue to make great strides in improving the safety and availability of transfused blood components around the globe and the record quarterly product revenue results reflect that progress. Product revenue growth was driven by strong global commercial execution and growing awareness of the benefits conferred by our INTERCEPT Blood System. Fu

Cerus Corporation (NASDAQ:CERS) announced today that its third quarter 2025 financial results will be released on Thursday, November 6, 2025, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event. A replay will be av

Second Quarter Total Revenue of $60.1 Million; Record Product Revenue of $52.4 Million, Up 16% Year-Over-Year Raising Full-Year 2025 Product Revenue Guidance Range to $200 Million - $203 Million Conference Call Today at 4:30 pm ET Cerus Corporation (NASDAQ:CERS) announced financial results for the second quarter ended June 30, 2025, and provided a business update. "With our singular focus to advance blood safety and availability around the globe by establishing INTERCEPT as the standard of care, this quarter's commercial results are evidence of the progress we are making in multiple geographies and across our INTERCEPT product portfolio. The early launch and adoption of our next gen

Cerus Corporation (NASDAQ:CERS) announced today that its second quarter 2025 financial results will be released on Tuesday, August 5, 2025, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event. A replay will be avai

First quarter 2025 Product Revenue of $43.2 Million, Up 13% Over Prior Year Reiterating Full-Year 2025 Product Revenue Guidance Range of $194 - $200 Million First Quarter 2025 Total Revenue of $48.9 Million Including Government Contract Revenue of $5.6 Million Conference Call Today at 4:30 pm ET Cerus Corporation (NASDAQ:CERS) announced today financial results for the first quarter ended March 31, 2025, and provided a business update. "We are off to a strong start in 2025, executing against our stated goals and making meaningful progress in advancing Cerus' mission to transform the safety and availability of transfused blood components," said William "Obi" Greenman, Cerus' president an

Cerus Corporation (NASDAQ:CERS) announced today that its first quarter 2025 financial results will be released on Thursday, May 1, 2025, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event. A replay wi

Full-Year and Fourth Quarter 2024 Product Revenues Increased 15% and 9%, respectively, from Prior Year Periods Fourth straight quarter of positive operating cash flows Reiterating Full-Year 2025 Product Revenue Guidance Range of $194 – $200 million Cerus Corporation (NASDAQ:CERS) today announced financial results for its full year and fourth quarter ended December 31, 2024. Recent highlights include: Total revenue for full-year 2024 and fourth quarter 2024 was comprised of (in thousands, except %): Three Months Ended           Twelve Months Ended         December 31,   Change   December 31,   Change   Unaudited  

Cerus Corporation (NASDAQ:CERS) announced today that its fourth quarter and full-year 2024 financial results will be released on Thursday, February 20, 2025, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of t

Third Quarter and First Nine-Month Product Revenue Increased 16% and 18%, respectively from Prior Year Periods Raising Full-Year 2024 Total Product Revenue Guidance to the Range of $177 million to $179 million and INTERCEPT Fibrinogen Complex Revenue Guidance to a range of $9 to $10 million Cerus Corporation (NASDAQ:CERS) today announced financial results for its third quarter and nine months ended September 30, 2024. Total revenue for the three and nine months ended September 30, 2024 was comprised of (in thousands, except %): Three Months Ended   Nine Months Ended September 30, Change   September 30, Change 2024   2023   $  

Cerus Corporation (NASDAQ:CERS) announced today that its third quarter 2024 financial results will be released on Wednesday, October 30, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event. A rep

Company to Host Conference Call and Webcast on Wednesday, October 16, 2024 at 5:00 p.m. EDT Cerus Corporation (NASDAQ:CERS) today announced updates on the INTERCEPT red blood cell (RBC) programs in the U.S. and in Europe: U.S. – New $248 million BARDA contract supports program beyond U.S. Phase 3 studies through anticipated PMA licensure and into commercialization Europe – CE Mark review has been concluded without approval; assessing strategy for anticipated future filing "We are pleased with the progress we have made with our U.S. RBC program, which will now receive additional support from BARDA through a new contract valued at up to $248 million, intended to fund activities includi

First Half of 2024 Product Revenue Increased 20% from Prior Year Period Increasing Full-Year 2024 Product Revenue Guidance Range from $172-175 Million to $175-178 Million Cerus Corporation (NASDAQ:CERS) today announced financial results for its second quarter and six months ended June 30, 2024. Total revenue for the three and six months ended June 30, 2024 was comprised of (in thousands, except %): Three Months Ended   Six Months Ended June 30, Change June 30, Change 2024 2023 $ % 2024 2023 $ % Product Revenue $ 45,079 $ 38,853 $

Cerus Corporation (NASDAQ:CERS) announced today that its second quarter 2024 financial results will be released on Thursday, August 1, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event. A rep

First Quarter Product Revenue Increased 24% from Prior Year Quarter Cerus Corporation (NASDAQ:CERS) today announced financial results for the first quarter ended March 31, 2024. Recent highlights include: First-quarter 2024 total revenue was comprised of (in thousands, except %): Three Months Ended March 31, Change 2024   2023   $   % Product Revenue $ 38,365 $ 30,974 $ 7,391   24% Government Contract Revenue   5,030   7,502   (2,472 ) -33% Total Revenue $ 43,395 $

Cerus Corporation (NASDAQ:CERS) announced today that its first quarter 2024 financial results will be released on Thursday, May 2, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event. A replay

Sequential Revenue Growth in the Fourth Quarter Driven by Sales in North America Narrowed GAAP Net Loss Attributable to Cerus Corporation to $1.3 Million for the Fourth Quarter and Achieved Goal of Adjusted EBITDA Breakeven for the Fourth Quarter Reiterating Full-Year 2024 Product Revenue Guidance Range of $172-175 Million Cerus Corporation (NASDAQ:CERS) today announced financial results for the fourth quarter and full year ended December 31, 2023. Recent highlights include: Fourth-quarter 2023 and full-year 2023 total revenue was comprised of (in thousands, except %):   Three Months Ended           Twelve Months Ended  

Cerus Corporation (NASDAQ:CERS) announced today that its fourth quarter and full-year 2023 financial results will be released on Tuesday, March 5, 2024, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the ev

Cerus Corporation (NASDAQ:CERS) today announced financial results for the third quarter ended September 30, 2023. Recent highlights include: Third quarter 2023 total revenue of $47.3 million was comprised of total product revenue of $39.8 million and government contract revenue of $7.5 million. Completed Phase 3 ReCePI study enrollment in cardiovascular surgery patients, with top-line data readout on track for Q1 2024. Attended first in-person AABB Annual Meeting since 2019, where presentations from transfusion medicine leaders highlighted the growing experience with the benefits of INTERCEPT-treated products, including INTERCEPT platelets and INTERCEPT Fibrinogen Complex (IFC).

Cerus Corporation (NASDAQ:CERS) announced today that its third quarter 2023 financial results will be released on Thursday, November 2, 2023, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event. A re

Cerus Corporation (NASDAQ:CERS) today announced financial results for the second quarter ended June 30, 2023. Recent highlights include: Second quarter 2023 total revenue of $47.7 million was comprised of total product revenue of $38.9 million and government contract revenue of $8.9 million. Received positive feedback for INTERCEPT Red Blood Cells CE Mark submission in clarification meeting with EU competent authority, the Dutch Medicines Evaluation Board (CBG), supporting possible CE Mark approval decision under the EU Medical Device Regulation (MDR) in the second half of 2024. Planned completion of Phase 3 ReCePI study enrollment in cardiovascular surgery patients this year, wi

Cerus Corporation (NASDAQ:CERS) announced today that its second quarter 2023 financial results will be released on Wednesday, August 2, 2023, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event. A re

Reiterating Full-Year 2023 Product Revenue Guidance Range of $165-170 Million Cerus Corporation (NASDAQ:CERS) today announced financial results for the first quarter ended March 31, 2023. Recent highlights include: First quarter 2023 total revenue of $38.5 million was comprised of (in thousands, except %):                 Three Months Ended           March 31, Change     2023     2022   $   % Product Revenue $ 30,974 $ 37,444 $ (6,470 ) -17 %

Cerus Corporation (NASDAQ:CERS) announced today that its first quarter 2023 financial results will be released on Thursday, May 4, 2023, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event. A replay

Strong Revenue Growth Driven by Sales in North America Product Revenue of $44.0 Million Grew 10% YoY in the Fourth Quarter Reiterating Full-Year 2023 Product Revenue Guidance Range of $165-170 Million Cerus Corporation (NASDAQ:CERS) today announced financial results for the fourth quarter and full year ended December 31, 2022. Recent highlights include: Fourth quarter 2022 and full-year 2022 total revenue was comprised of (in thousands, except %): Three Months Ended   Twelve Months Ended December 31, Change   December 31, Change 2022   2021   $   % 2022   2021   $   % Product Revenue $ 44,0

Cerus Corporation (NASDAQ:CERS) announced today that its fourth quarter and full year 2022 financial results will be released on Tuesday, February 28, 2023, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the

Total Revenue of $46.3 Million Grew 10% YoY in the Third Quarter Product Revenue of $39.6 Million Grew 10% YoY in the Third Quarter despite 6% FX headwind Cerus Corporation (NASDAQ:CERS) today announced financial results for the third quarter ended September 30, 2022. Recent developments and highlights include: Third quarter 2022 total revenue of $46.3 million, reflecting a 10% increase over the third quarter of 2021. Total revenue was composed of (in thousands, except %): Three Months Ended       Nine Months Ended     September 30,   Change   September 30,   Change 2022   2021   %   2022   2021   %

Cerus Corporation (NASDAQ:CERS) announced today that its third quarter 2022 financial results will be released on Thursday, November 3, 2022, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event. A repl

Second Quarter 2022 is Highest Product Revenue in Company History Total Revenue of $47.6 Million Grew 26% YoY in the Second Quarter Product Revenue of $41.0 Million Grew 30% YoY in the Second Quarter Reiterating Full-Year 2022 Product Revenue Guidance Range of $160-165 Million Cerus Corporation (NASDAQ:CERS) today announced financial results for the second quarter ended June 30, 2022. Recent developments and highlights include: Second quarter 2022 total revenue of $47.6 million, reflecting a 26% increase over the prior year period. Total revenue was composed of (in thousands, except %):     Three Months Ended             Six Months Ended      

Cerus Corporation (NASDAQ:CERS) announced today that its second quarter 2022 financial results will be released on Thursday, August 4, 2022, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Participants may register for the call here. While not required, interested participants are encouraged to join 10 minutes prior to the start of the event. A repla

Growth From All Geographic Regions with Results Driven by INTERCEPT Platelet Uptake in the U.S. Total Revenue of $43.0 Million Grew 46% YoY in the First Quarter Product Revenue of $37.4 Million Grew 60% YoY in the First Quarter Increasing Full-Year 2022 Product Revenue Guidance Range from $157-164 Million to $160-165 Million Cerus Corporation (NASDAQ:CERS) today announced financial results for the first quarter ended March 31, 2022. Recent developments and highlights include: First quarter 2022 total revenue of $43.0 million, reflecting a 46% increase over the prior year period. Total revenue was composed of (in thousands, except %):   Three Months Ended     Marc

Cerus Corporation (NASDAQ:CERS) announced today that its first quarter 2022 financial results will be released on Thursday, May 5, 2022, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Alternatively, you may access the live conference call by dialing (866) 235-9006 (U.S.) or (631) 291-4549 (international). A replay will be available on Cerus' website

Strong Revenue Growth Driven by U.S. Adoption of INTERCEPT Platelets Total Revenue of $50.1 Million Grew 49% in the Fourth Quarter Product Revenue of $39.9 Million Grew 41% in the Fourth Quarter Reiterating Full-Year 2022 Product Revenue Guidance Range of $157-$164 Million Cerus Corporation (NASDAQ:CERS) today announced financial results for the fourth quarter and full year ended December 31, 2021. Recent developments and highlights include: Fourth quarter 2021 total revenue of $50.1 million, reflecting a 49% increase over the prior year period. For the full year, 2021 total revenue was $159.5 million, reflecting a 40% increase over the prior year period. Total revenue was composed o

Cerus Corporation (NASDAQ:CERS) announced today that its fourth quarter and full-year 2021 financial results will be released on Tuesday, February 22, 2022, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Alternatively, you may access the live conference call by dialing (866) 235-9006 (U.S.) or (631) 291-4549 (international). A replay will be availab

Accelerating Revenue Growth Driven by U.S. Adoption of INTERCEPT Platelets Total Revenue of $42.1 Million Grew 44% in the Third Quarter Product Revenue of $36.1 Million Grew 53% in the Third Quarter Full-Year 2021 Product Revenue Guidance Range Raised to $127-129 Million Cerus Corporation (NASDAQ:CERS) today announced financial results for the third quarter ended September 30, 2021. Recent developments and highlights include: Third quarter 2021 total revenue of $42.1 million, reflecting a 44% increase over the prior year period. Total revenue was composed of (in thousands, except %):   Three Months Ended         Nine Months Ended         Septemb

Cerus Corporation (NASDAQ:CERS) announced today that its third quarter 2021 financial results will be released on Tuesday, November 2, 2021, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Alternatively, you may access the live conference call by dialing (866) 235-9006 (U.S.) or (631) 291-4549 (international). A replay will be available on Cerus' web

Highest Quarterly Total and Product Revenue in Company History Total Revenue of $37.8 Million Grew 41% in Second Quarter Product Revenue of $31.5 Million Led by 128% Growth in North America as INTERCEPT Platelet Sales Ramped in the U.S. Full-Year 2021 Product Revenue Guidance Range Raised to $118-122 Million Cerus Corporation (NASDAQ:CERS) today announced financial results for the second quarter ended June 30, 2021. Recent developments and highlights include: Second quarter 2021 total revenue of $37.8 million, reflecting a 41% increase over the prior year period. Total revenue was composed of (in thousands, except %):     Three Months Ended            

Cerus Corporation (NASDAQ:CERS) announced today that its second quarter 2021 financial results will be released on Tuesday, August 3, 2021, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET that afternoon, during which management will discuss the Company's financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Relations page of the Cerus website at http://ir.cerus.com. Alternatively, you may access the live conference call by dialing (866) 235-9006 (U.S.) or (631) 291-4549 (international). A replay will be available on Cerus' webs

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced that the US Food and Drug Administration (FDA) has granted approval of the INTERCEPT Blood System for Cryoprecipitation. The system is used to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. After thawing, Pathogen Reduced Cryoprecipitated Fibrinogen Complex remains transfusion-ready at room temperature for up to 5 days, continuously available for administration over this extended period. This product has been granted FDA Breakthrough Device designation based on the potential t